TAO Synergies
New York · Founded 2012
About TAO Synergies
TAO Synergies is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKC╧╡) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-╬▓ degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
Company Facts
- Founded: 2012
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $79.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:TAOX
- Website: taosynergies.com
- Phone: 973-242-0005
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tao-synergies-141010 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.